Moderna’s Omicron-targeted bivalent COVID-19 booster shot, which combines the company’s original Spikevax COVID-19 vaccine and a separate vaccine candidate targeting the Omicron variant, showed promise against the Omicron variant.

The booster dose, which was studied in 437 participants, showed a better neutralizing antibody response against the Omicron variant one month after administration compared with the original Spikevax.

Moderna is submitting the preliminary data and analysis to regulatory authorities and anticipates that the Omicron-specific booster will be available in the late summer.